Accession Number : ADA446263


Title :   Vitamin D-Prostaglandin Interactions and Effects on Prostate Cancer


Descriptive Note : Annual summary rept. 15 Sep 2004-15 Sep 2005


Corporate Author : LELAND STANFORD JUNIOR UNIV STANFORD CA


Personal Author(s) : Moreno, Jacqueline


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a446263.pdf


Report Date : Oct 2005


Pagination or Media Count : 61


Abstract : Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of cancer death in North American men [1]. According to the American Cancer Society more than 232,000 men will be diagnosed with PCa in 2005 and approximately 10% of these men will die of the disease [1]. Primary therapy for PCa involves the removal of the prostate by surgery or radiation therapy. Unfortunately, after initial treatment PCa often recurs. Androgens regulate normal prostate development and growth. Surgical or medical androgen deprivation has been used as the standard treatment for PCa that fails primary therapy [2, 3]. Although there is a good initial response to androgen ablation in most men, tumors will progress to androgen independence resulting in death {4] since there is currently no adequate treatment for this advanced disease. Our current investigation is aimed at the development of new therapies to treat PCa. la,25- Dihydroxyvitamin D3 (calcitriol), the hormonally active form of vitamin D, is a promising new therapeutic agent for PCa therapy [5-15].


Descriptors :   *VITAMIN D , *PROSTATE CANCER , ENZYMES , THERAPY , GENES , ANDROGENS , PROSTAGLANDIN , CELLS(BIOLOGY) , DEPRIVATION , PROSTATE GLAND


Subject Categories : Biochemistry
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE